Evolent Health (EVH)

• Market cap: $1.15B
• 1 day: -1.57%
• 5 days: -19.35%
• 1 month: -8.00%
• 3 months: -59.94%
• 6 months: -52.04%
• Year to date: -12.97%
• 1 year: -67.27%
• 5 years: -12.13%
• 10 years: -46.98%
• Sector: Industrials
• Industry: Management Services

About: Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Employees: 4,700

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

75% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 7 (+3) [Q3]

49% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 39

45% more capital invested

Capital invested by funds: $2.58B [Q2] → $3.73B (+$1.15B) [Q3]

7% more funds holding

Funds holding: 243 [Q2] → 259 (+16) [Q3]

2.35% less ownership

Funds ownership: 116.06% [Q2] → 113.71% (-2.35%) [Q3]

10% less call options, than puts

Call options by funds: $75.4M | Put options by funds: $84.2M

20% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 92

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $14 40% upside
• Avg. target: $17.73 77% upside
• High target: $28 180% upside

11 analyst ratings

• positive: 10 91%
• neutral: 1 9%
• negative: 0 0%

UBS Kevin Caliendo 65% 1-year accuracy 11 / 17 met price target	40% upside $14	Buy Maintained	16 Jan 2025
Needham Ryan MacDonald 56% 1-year accuracy 38 / 68 met price target	50% upside $15	Buy Reiterated	15 Jan 2025
RBC Capital Sean Dodge 48% 1-year accuracy 21 / 44 met price target	70% upside $17	Outperform Maintained	14 Jan 2025
Truist Securities Jailendra Singh 31% 1-year accuracy 11 / 35 met price target	100% upside $20	Buy Maintained	13 Jan 2025
Citigroup Daniel Grosslight 39% 1-year accuracy 9 / 23 met price target	80% upside $18	Buy Maintained	10 Jan 2025